1. Home
  2. EZGO vs EOCN Comparison

EZGO vs EOCN Comparison

Compare EZGO & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EZGO Technologies Ltd.

EZGO

EZGO Technologies Ltd.

SELL

Current Price

$1.78

Market Cap

2.4M

ML Signal

SELL

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$1.84

Market Cap

2.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EZGO
EOCN
Founded
2014
2000
Country
China
Israel
Employees
N/A
N/A
Industry
Motor Vehicles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.9M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
EZGO
EOCN
Price
$1.78
$1.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 80.9K
8.9K
Earning Date
12-29-2026
12-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$1.79
52 Week High
$3.30
$3.80

Technical Indicators

Market Signals
Indicator
EZGO
EOCN
Relative Strength Index (RSI) 70.93 22.75
Support Level $0.83 N/A
Resistance Level $2.46 $2.98
Average True Range (ATR) 0.25 0.30
MACD 0.04 -0.08
Stochastic Oscillator 75.49 1.64

Price Performance

Historical Comparison
EZGO
EOCN

About EZGO EZGO Technologies Ltd.

EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Share on Social Networks: